LONDON – Oct. 30, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful antitumor payloads directly to the tumor, is today hosting a live R&D Spotlight: “Next Generation of pre|CISION® Medicines” in London.
Avacta’s unique proprietary technology allows for targeted delivery of cytotoxic drugs (the “payload”) in the tumor microenvironment (TME). The presentations will cover the Company’s next generation of follow-on candidates with their unique features and patient populations.
Avacta will highlight in this event the novel pre|CISION® candidates in the evolving pipeline, details of which were presented at the EORTC-NCI-AACR Triple Meeting in Barcelona last week and provide further detail on their properties and patient populations.
Avacta’s AVA6000, AVA6103, and AVA7100 programs are highly differentiated pipeline assets, addressing large markets. The presentation will also address these programs’ near-term milestones.
Avacta will highlight the franchise it has developed in breast cancer and how these therapies in this indication will move forward.
The Company confirms that the process to divest the revenue-generating diagnostics division is ongoing and it continues to actively explore opportunities for a potential dual listing on NASDAQ. No additional financial information will be disclosed.
This event is open to both analysts and investors, further details are provided on the Company website and a recording of the event will be made available in due course.